Metabolon Partners with Craig Venter's Human Longevity, Inc.


Metabolon Partners with Craig Venter's Human Longevity, Inc.

Metabolon Enters Into Collaboration Agreement with Human Longevity Inc. to Provide Metabolomic Profiling Services

  • Founded by J. Craig Venter, Human Longevity is building the world’s most comprehensive database of human genotypes and phenotypes
  • Metabolon to carry out small molecule analysis on 10,000 subjects in the initial phase of the collaboration

RESEARCH TRIANGLE PARK, N.C. (March 5, 2014) – Metabolon, Inc., the world’s leading commercial-stage metabolomics company, announces the signing of an agreement with newly-launched Human Longevity Inc. (HLI), whereby Metabolon will provide biochemical profiling services to assist HLI in its mission to tackle diseases of aging by building the world’s largest and most complete human genotype, microbiome and phenotype database. In the initial term of the agreement Metabolon will carry out small molecule analysis of 10,000 subjects and collaborate with HLI to map changes in the small molecules to end points of disease and gene mutations.
HLI cofounders are J. Craig Venter, Ph.D., Robert Hariri, M.D., Ph.D. and Peter H. Diamandis, M.D.  Dr. Venter, who is well known for leading Celera to the successful sequencing of the human genome, has been a member of Metabolon’s Scientific Advisory Board since 2003.
Under the agreement Metabolon will apply its leading metabolomics technology to augment the genetic and microbiome information HLI is collecting. Metabolon’s metabolomic approach identifies the full complement of metabolites present in a human biological specimen. Metabolomics is important because quantifying and understanding the full picture of circulating biochemicals in the body can help researchers get a clearer picture of that individual’s health status, and provide markers and pathways associated with disease and drug action. In addition, Metabolon will collaborate with HLI to identify small molecule biomarkers of disease, which Metabolon may then use to develop small molecule diagnostic tests.
Commenting on the agreement Dr. Venter said, “The establishment of HLI is the next step beyond the sequencing of the human genome, and may at last provide useful clinical information for the treatment of disease that was lacking from genome mapping alone.  Metabolon is a visionary and leader in the field of metabolomics, and I have great confidence in the company’s technology and ability to add significant value to HLI. Because of my position as a member of Metabolon’s Scientific Advisory Board, I have a deep personal appreciation of the company’s impressive methods and scientific expertise.”
John Ryals, Ph.D., Metabolon’s chief executive officer, said, “We are delighted to be aligned with HLI and the world-renowned scientific minds behind this new company.  It is thrilling to have the opportunity to make key contributions to the study of aging and we look forward to realizing the benefits of discovery.”
About Human Longevity Inc. (HLI)
HLI, a privately held company headquartered in San Diego, Calif., was founded in 2013 by the pioneers in the fields of genomics and stem cell therapy. Using advances in genomic sequencing, the human microbiome, proteomics, informatics, computing and cell therapy technologies, HLI is building the world’s most comprehensive database of human genotypes and phenotypes as a basis for a variety of commercialization opportunities to help solve aging related disease and human biological decline. HLI will be licensing access to its database, and developing new diagnostics and therapeutics as part of their product offerings. For more information please visit,
About Metabolon
We are the world’s leading commercial-stage metabolomics company, with a focus on improving patient healthcare by leading a fundamental change in the diagnosis of obesity-related disease and cancer. Metabolomics is a rapidly evolving field of biochemical research and discovery. Our proprietary metabolomic technology enables us to discover innovative, non-invasive, cost-effective diagnostic tests. Our marketed diagnostic tests and tests in development are aimed at providing physicians with information they can use to intervene early to prevent or more effectively treat disease. For more information visit, email or call 919-572-1711.
Cautionary Note about Forward-Looking Statements
The materials provided herein that are not historical facts are or might constitute projections and other forward-looking statements regarding future events that involve substantial risks, uncertainties, and assumptions. If any of these risks or uncertainties materializes or if any of these assumptions prove incorrect, the results could differ materially from the results expressed or implied by any forward-looking statements. The risks, uncertainties, and assumptions referred to above include, but are not limited to: the uncertainties inherent in biochemical research and development; decisions by regulatory authorities regarding whether and when to approve diagnostic tests; our and our distributors’ ability to successfully commercialize and market both new and existing products; governmental laws and regulations affecting health care, including regarding access, pricing and reimbursement of diagnostic tests; the strength of our intellectual property portfolio; our history of losses; whether we are able to achieve or sustain profitability; our highly competitive industry; our ability to compete effectively; security and privacy risks; and our ability to continue to innovate and provide products and services that are useful to our clients, among other risks, uncertainties, and assumptions.
MEDIA Contact
John Ryals
#   #   #